Clinical Trial

Iceland Screens, Treats or Prevents Multiple Myeloma

Study acronym: iStopMM
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-10-26; most recent amendment 2025-09-24.
Status change: Recruiting → Active, Not Recruiting 2018-11-19
Trial Details
NCT Number NCT03327597
Lead Sponsor University of Iceland
Collaborators: Landspitali University Hospital, Union for International Cancer Control, Icelandic Heart Association, deCODE genetics, International Myeloma Foundation/Black Swan Research Initiative, The Binding Site, Memorial Sloan Kettering Cancer Center, European Research Council, Icelandic Research Center
Conditions Monoclonal Gammopathy of Undetermined Significance
Enrollment 80,761 participants
Start Date 2016-09-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-30